P I Industries

Q1 FY27Fertilizers & Agrochemicals

P I Industries Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book

Q1 FY27 earnings call: what management guided on revenue, margins and order book.

Price₹2,479

Market cap₹37.9K Cr

P/E35.1

Updated25 Aug 2026

Read4 min read

What the Q1 FY27 call signalled

1 of 3 strong

RevenueRank 4

MarginRank 3

CapexYes

Not discussed on this call: fundraise, order book.

The short version

FY27 revenue growth guidance expected to be in the lower single-digit range, subject to industry cycle and conditions. PI Industries expects a positive growth trajectory for FY27, with revenue growth in the lower single digits, contingent on industry cycles and conditions.

From P I Industries's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.

Revenue & Sales Performance

Rank 4

FY27 revenue growth guidance expected to be in the lower single-digit range, subject to industry cycle and conditions.
Positive growth trajectory anticipated, especially recovery in exports in the second half of FY27 supported by new product launches.
Domestic market volume growth of 12% in Q1 FY27, translating to 3% revenue growth; outlook improving with better monsoon conditions.
Biologicals showing aggressive growth of 50% with a 3-year CAGR of 15%, with expansion in global markets like Brazil, Mexico, Europe, and the US.
New product launches planned across Agchem, Electronics, and Pharma segments, with 4-5 new molecules expected in FY27.
New generation and innovative products targeted for at least three-digit million-dollar revenue potential over medium to long term.
Long-term confidence in double-digit market shares for products like the Brazil nematicide, expected to develop over 5-10 years with technology acceleration.
Overall, revenue growth is being built on sustainable, innovation-led platforms supported by R&D investments (3-4% of revenues).

Profitability & Margins

PI Industries expects a positive growth trajectory for FY27, with revenue growth in the lower single digits, contingent on industry cycles and conditions.
EBITDA margin is anticipated to be maintained through product mix optimization and cost management amid geopolitical and commodity price challenges.
The company is investing heavily in R&D (3-4% of revenue) and biologicals business, which currently impacts EBITDA but is viewed as value creation for sustainable long-term growth.
Biologicals segment shows aggressive growth (50% quarterly growth, 15% CAGR over three years), with global expansion underway.
Pharma segment is in early stages; scale-up expected to reduce operating volatility and improve profitability over time.
Capex guidance is Rs. 700-800 crore for FY27, supporting expansion in manufacturing and innovation.
Overall, PI Industries remains confident in medium to long-term growth driven by innovation, new product launches, and gradual scaling of new business verticals.

See what P I Industries said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Yes

FY27 capex guidance is Rs. 700 to Rs. 800 crore, maintaining steady investment momentum.
Current capex (~Rs. 250 crore in Q1) allocated across:
- Existing manufacturing asset enhancements
- New verticals development
- Innovation-led approaches in geographies and products
Investment focused on building sustainable, advanced capabilities in Agchem, Pharma, and Electronic/Specialty chemicals.
Emphasis on commissioning world’s largest flow chemistry plants enabling sustainable, safer, and cost-efficient production.
Strategic investments made to support global biologicals platform scaling, including field trials and grower engagements.
Continued capex to support transition to fully integrated CRDMO model in Pharma and expansion of innovation pipelines.
Capital disciplined with focus on working capital efficiency and maintaining net cash position for flexibility in future strategic opportunities.

Top-ranked in Fertilizers & Agrochemicals

Ranked on what management guided this quarter

5x potential

1Anya Polytech &₹180 Cr

Rev 2Mar 1

2Dharmaj Crop Guard Ltd₹911 Cr

Rev 2Mar 2

3₹5.6K Cr

Rev 2Mar 3

4₹1.3K Cr

Rev 3Mar 1

5₹56.9K Cr

Rev 3Mar 3

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

No explicit mention of any current or future fundraising through debt or equity in the transcript.
The company highlights a strong, debt-free balance sheet with net cash of INR 38 billion, providing strategic flexibility.
Capex guidance for FY27 is Rs. 700 to Rs. 800 crore, funded through existing resources without indicating new borrowings.
Investments and losses in subsidiaries, especially biologics and pharma segments, are being funded internally as part of strategic growth.
No comment on raising fresh equity or debt; focus is on disciplined capital allocation and net working capital management to drive growth.

See what P I Industries said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The current order book is cited at approximately USD 1.2 billion, which is stable sequentially.
The company expects continued order inflows, particularly in Pharma CRDMO, Biologicals, and Agchem segments.
There are some sequential delays in pharma order book transitions, but the orders are largely securitized and expected to convert over time.
The business is in early stages for pharma and biologicals with some volatility; as scale and portfolio expand, volatility will reduce.
The company has locked in partnerships for integrated drug discovery and chemical manufacturing, which supports future order pipeline.
New product launches and growing traction in exports and biological markets also contribute to order pipeline strength.

P I Industries — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹1.6K Cr, net profit ₹200 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What P I Industries Ltd's management said in earlier quarters

Others in Fertilizers & Agrochemicals this season

Indogulf Cropsciences Ltd (Q1 FY27)
1800+ crores within 2-3 years. Key concall takeaways from Indogulf Cropsciences Ltd's Q1 FY27 earnings call — and how it ranks against sector peers.
Gujarat State Fertilizers & Chemicals Ltd (Q1 FY27)
Profit after tax increased by 15% YoY in Q1 FY27, signaling positive growth trajectory. Key concall takeaways from Gujarat State Fertilizers & Chemicals Ltd's…
GSP Crop Science Ltd (Q1 FY27)
Capacity utilization indicates room for growth: 70-75% for technical and 25-30% for formulations. Key concall takeaways from GSP Crop Science Ltd's Q1 FY27…
Rallis India Ltd (Q1 FY27)
. Key concall takeaways from Rallis India's Q1 FY27 earnings call — and how it ranks against sector peers.

Compare:vs Coromandel International Ltd vs Fertilizers & Chemicals Travancore Ltd vs UPL Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were P I Industries Q1 FY27 results?

What is P I Industries share price analysis?

P I Industries currently shows a neutral. The stock trades at a P/E of 35.1 with a market cap of ₹37,881 Cr. Investors should review the full earnings analysis for detailed insights.

Is P I Industries planning capital expenditure?

FY27 capex guidance is Rs.

Keep P I Industries on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.